Aurinia PharmaceuticalsAUPH
AUPH
About: Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Employees: 300
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 19
27% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 49
22% more capital invested
Capital invested by funds: $426M [Q3] → $518M (+$92.4M) [Q4]
9% more funds holding
Funds holding: 179 [Q3] → 195 (+16) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
0.35% less ownership
Funds ownership: 40.64% [Q3] → 40.29% (-0.35%) [Q4]
21% less call options, than puts
Call options by funds: $13.3M | Put options by funds: $16.8M
Research analyst outlook
We haven’t received any recent analyst ratings for AUPH.
Financial journalist opinion
Neutral
24/7 Wall Street
3 weeks ago
Insiders Are Loading Up on These 4 Biotech Stocks Now
Things are heating up in the biotechnology space, with a flurry of recent initial public offerings and some notable insider purchases of the past week or so.
Neutral
Benzinga
1 month ago
Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations
On Thursday, Aurinia Pharmaceuticals Inc AUPH reported fourth-quarter earnings of 1 cent per share, compared to a loss of 19 cents a year ago and the consensus loss of 2 cents.
Neutral
Seeking Alpha
1 month ago
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2024 Earnings Call Transcript
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications and Investor Relations Peter Greenleaf - President, Chief Executive Officer and Director Joe Miller - Chief Financial Officer Greg Keenan - Chief Medical Officer Conference Call Participants Vishwesh Shah - TD Cowen Olivia Brayer - Cantor Fitzgerald Farzin Haque - Jefferies Will Soghikian - Leerink Partners Ed Arce - H.C. Wainwright Operator Greetings, and welcome to the Aurinia Pharmaceuticals Fourth Quarter and Full-Year 2024 Earnings Call.
Positive
Zacks Investment Research
1 month ago
Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to loss of $0.19 per share a year ago.
Neutral
Business Wire
1 month ago
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress.
Positive
Seeking Alpha
1 month ago
Aurinia Pharmaceuticals: There's Still Time For Sales Growth
AUPH's Lupkynis showed modest revenue growth from Q2'24 to Q3'24, but limited sales growth going from Q2 to Q3 has been seen previously. Full-year 2024 net product revenue guidance of $210M-$220M appears achievable, with $158.6M already reported and Q4 typically outperforming Q3. Potential competitors in lupus nephritis and even in systemic lupus erythematosus include Roche and Biogen.
Neutral
Business Wire
1 month ago
Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025.
Positive
Zacks Investment Research
2 months ago
Aurinia (AUPH) Upgraded to Buy: Here's Why
Aurinia (AUPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Seeking Alpha
2 months ago
3 Biotech Stocks With Notable Insider Buying
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners.
Positive
24/7 Wall Street
3 months ago
Insiders Are Loving These 6 Stocks Right Now
The year is winding down, and the stock markets are near all-time highs. Opinions on what the new year will bring vary wildly.
Charts implemented using Lightweight Charts™